{"id":54550,"date":"2023-03-06T23:07:40","date_gmt":"2023-03-06T22:07:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/"},"modified":"2023-03-06T23:07:40","modified_gmt":"2023-03-06T22:07:40","slug":"alpha-cognition-provides-private-placement-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/","title":{"rendered":"Alpha Cognition Provides Private Placement Update"},"content":{"rendered":"
\n

\nNot for distribution in the United States or to U.S. newswire services<\/b>\n<\/p>\n

VANCOUVER, British Columbia–(BUSINESS WIRE)–Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (\u201cAlpha Cognition<\/b>\u201d, or the \u201cCompany<\/b>\u201d), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, announces that the Company expects to complete the second tranche of its ongoing private placement offering prior to March 17, 2023. Please see the Company\u2019s February 16, 2023 news release for additional information on the offering.\n<\/p>\n

<\/a><\/p>\n

\nThis news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the \u201c1933 Act<\/b>\u201d) or any state securities laws, and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.\n<\/p>\n

\nAbout Alpha Cognition Inc.<\/b>\n<\/p>\n

\nAlpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS), for which there are limited treatment options.\n<\/p>\n

\nALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for traumatic brain injury.\n<\/p>\n

\nNeither TSX Venture Exchange (the \u201cTSX-V\u201d), OTC Markets Group, nor the TSX-V\u2019s Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.<\/i>\n<\/p>\n

\nForward-looking Statements<\/b>\n<\/p>\n

\nThis news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward\u2010looking statement that reflects the Company\u2019s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2010looking statements by the words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward\u2010looking statements may include statements regarding closing of the Offering, the Company\u2019s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward\u2010looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward\u2010looking statements for any reason, even if new information becomes available in the future.\n<\/p>\n

Contacts<\/b> <\/p>\n

\ninfo@alphacognition.com<\/a>
https:\/\/www.alphacognition.com\/<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Not for distribution in the United States or to U.S. newswire services VANCOUVER, British Columbia–(BUSINESS WIRE)–Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (\u201cAlpha Cognition\u201d, or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, announces that the Company expects to complete the second tranche of its ongoing private placement offering prior to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54550","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlpha Cognition Provides Private Placement Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpha Cognition Provides Private Placement Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Not for distribution in the United States or to U.S. newswire services VANCOUVER, British Columbia–(BUSINESS WIRE)–Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (\u201cAlpha Cognition\u201d, or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, announces that the Company expects to complete the second tranche of its ongoing private placement offering prior to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-06T22:07:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230306005821\/en\/1731351\/21\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Alpha Cognition Provides Private Placement Update\",\"datePublished\":\"2023-03-06T22:07:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/\"},\"wordCount\":617,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005821\\\/en\\\/1731351\\\/21\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/\",\"name\":\"Alpha Cognition Provides Private Placement Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005821\\\/en\\\/1731351\\\/21\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\",\"datePublished\":\"2023-03-06T22:07:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005821\\\/en\\\/1731351\\\/21\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230306005821\\\/en\\\/1731351\\\/21\\\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alpha-cognition-provides-private-placement-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha Cognition Provides Private Placement Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpha Cognition Provides Private Placement Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/","og_locale":"en_US","og_type":"article","og_title":"Alpha Cognition Provides Private Placement Update - Pharma Trend","og_description":"Not for distribution in the United States or to U.S. newswire services VANCOUVER, British Columbia–(BUSINESS WIRE)–Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (\u201cAlpha Cognition\u201d, or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, announces that the Company expects to complete the second tranche of its ongoing private placement offering prior to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-06T22:07:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230306005821\/en\/1731351\/21\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Alpha Cognition Provides Private Placement Update","datePublished":"2023-03-06T22:07:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/"},"wordCount":617,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230306005821\/en\/1731351\/21\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/","url":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/","name":"Alpha Cognition Provides Private Placement Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230306005821\/en\/1731351\/21\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","datePublished":"2023-03-06T22:07:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230306005821\/en\/1731351\/21\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230306005821\/en\/1731351\/21\/Alpha_Cognition_Inc._-_Logo_Left_Side%2C_Dark_Colour.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alpha-cognition-provides-private-placement-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Alpha Cognition Provides Private Placement Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54550"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54550\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}